RATIONALE: MDMA is one of the most widely consumed recreational drugs in Europe. However, the mechanisms involved in the reinforcing properties of MDMA are still unclear. In this sense, the establishment of a reliable model of MDMA self-administration in mice could represent an important approach to study the neuronal substrates associated with MDMA reward by using genetically modified mice. OBJECTIVES: To develop a reliable model of operant intravenous MDMA self-administration in drug-naïve mice. MATERIALS AND METHODS: Mice were trained to acquire intravenous self-administration of MDMA at different doses (0, 0.06, 0.125, 0.25, 0.5 and 1.0 mg/kg/infusion) on a FR1 schedule of reinforcement for 15 consecutive days. The motivational value of different doses of MDMA (0.125, 0.25 and 0.5 mg/kg/infusion) was then tested using a progressive ratio paradigm. Finally, [3H]-mazindol autoradiographic studies were carried out in order to quantitatively assess presynaptic dopamine transporter (DAT) binding sites in the striatum of mice trained to self-administer MDMA (0 and 1.0 mg/kg/infusion) during 15 days. RESULTS: The latency for discrimination between the active and inactive holes, as well as the number of animals acquiring stability criteria, varied as a function of the dose of MDMA. The mice responding for intermediate doses (0.125, 0.25 and 0.5 mg/kg/infusion) discriminated earlier than those responding for low (0.06 mg/kg/infusion) or high (1.0 mg/kg/infusion) doses. The percentage of animals achieving stability criteria increased with days of testing and was inversely proportional to the dose of MDMA. The breaking points achieved for doses of 0.125 and 0.25 mg/kg/infusion were significantly higher than for a dose of 0.5 mg/kg/infusion. No significant DAT neurotoxicity was observed in the striatum of animals self-administering MDMA at a dose of 1 mg/kg/infusion. CONCLUSIONS: The present results show that MDMA can be reliably self-administered by drug-naïve mice.
RATIONALE: MDMA is one of the most widely consumed recreational drugs in Europe. However, the mechanisms involved in the reinforcing properties of MDMA are still unclear. In this sense, the establishment of a reliable model of MDMA self-administration in mice could represent an important approach to study the neuronal substrates associated with MDMA reward by using genetically modified mice. OBJECTIVES: To develop a reliable model of operant intravenous MDMA self-administration in drug-naïve mice. MATERIALS AND METHODS:Mice were trained to acquire intravenous self-administration of MDMA at different doses (0, 0.06, 0.125, 0.25, 0.5 and 1.0 mg/kg/infusion) on a FR1 schedule of reinforcement for 15 consecutive days. The motivational value of different doses of MDMA (0.125, 0.25 and 0.5 mg/kg/infusion) was then tested using a progressive ratio paradigm. Finally, [3H]-mazindol autoradiographic studies were carried out in order to quantitatively assess presynaptic dopamine transporter (DAT) binding sites in the striatum of mice trained to self-administer MDMA (0 and 1.0 mg/kg/infusion) during 15 days. RESULTS: The latency for discrimination between the active and inactive holes, as well as the number of animals acquiring stability criteria, varied as a function of the dose of MDMA. The mice responding for intermediate doses (0.125, 0.25 and 0.5 mg/kg/infusion) discriminated earlier than those responding for low (0.06 mg/kg/infusion) or high (1.0 mg/kg/infusion) doses. The percentage of animals achieving stability criteria increased with days of testing and was inversely proportional to the dose of MDMA. The breaking points achieved for doses of 0.125 and 0.25 mg/kg/infusion were significantly higher than for a dose of 0.5 mg/kg/infusion. No significant DATneurotoxicity was observed in the striatum of animals self-administering MDMA at a dose of 1 mg/kg/infusion. CONCLUSIONS: The present results show that MDMA can be reliably self-administered by drug-naïve mice.
Authors: Guadalupe Soria; Victoria Mendizábal; Clara Touriño; Patricia Robledo; Catherine Ledent; Marc Parmentier; Rafael Maldonado; Olga Valverde Journal: Neuropsychopharmacology Date: 2005-09 Impact factor: 7.853
Authors: R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí Journal: Br J Clin Pharmacol Date: 2000-02 Impact factor: 4.335
Authors: Patricia Robledo; Jose M Trigo; Fany Panayi; Rafael de la Torre; Rafael Maldonado Journal: Psychopharmacology (Berl) Date: 2007-08-08 Impact factor: 4.530
Authors: Sarah M Dickerson; Deena M Walker; Maria E Reveron; Christine L Duvauchelle; Andrea C Gore Journal: Neuroendocrinology Date: 2008-02-29 Impact factor: 4.914
Authors: Jessica Ruiz-Medina; Ana Pinto-Xavier; Marta Rodríguez-Arias; José Miñarro; Olga Valverde Journal: Psychopharmacology (Berl) Date: 2012-11-29 Impact factor: 4.530
Authors: Miquel Martin; Miriam Gutiérrez-Martos; Roberto Cabrera; Klaus Langohr; Rafael Maldonado; Magi Farre; Rafael de la Torre Journal: Psychopharmacology (Berl) Date: 2021-04-11 Impact factor: 4.530
Authors: Antonio Vidal-Infer; Concepción Roger-Sánchez; Manuel Daza-Losada; María A Aguilar; José Miñarro; Marta Rodríguez-Arias Journal: PLoS One Date: 2012-08-16 Impact factor: 3.240